Medicine and Dentistry
Uterine Cancer
100%
Ovarian Cancer
70%
Neoplasm
60%
Gynecological Oncology
59%
Malignant Neoplasm
45%
Overall Survival
32%
Metastatic Carcinoma
28%
Cancer
25%
Diseases
23%
Progression Free Survival
22%
Paclitaxel
20%
Radiation Therapy
16%
Cell Line
15%
Protein Tyrosine Kinase
14%
Female Genital Tract Cancer
14%
Fallopian Tube
14%
Pelvis
14%
Arm
13%
Body Mass Index
12%
Cervical Cancer
12%
Magnetic Resonance Imaging
12%
Squamous Cell Carcinoma
11%
Randomized Controlled Trial
11%
Cancer Cell
10%
Photoacoustic Microscopy
10%
COVID-19
10%
Phase II Trials
10%
Recurrent Ovarian Cancer
10%
Vulva
10%
Cancer Surgery
10%
Oncology
10%
Clinical Trial
10%
In Vitro
10%
Lymph Node Metastasis
9%
Recurrent Disease
9%
Patient Referral
8%
Quality of Life
8%
Biological Marker
8%
Surgery
8%
Comorbidity
8%
Paraaortic Lymph Node
8%
Poly ADP Ribose Polymerase
8%
Biopsy Technique
7%
Primary Health Care
6%
Tumor Cell
6%
Programmed Cell Death
6%
Protein Expression
6%
Logistic Regression Analysis
6%
Cancer Therapy
6%
Sensitivity and Specificity
6%
Keyphrases
Endometrial Cancer
74%
Ovarian Cancer
56%
Gynecologic Oncology
43%
Overall Survival
31%
Tumor
29%
Oncology Patients
28%
Gynecologic Oncology Group
27%
Cancer Patients
22%
Group Studies
21%
Obesity
20%
Paclitaxel
19%
Chemotherapy
18%
Radiation Therapy
16%
Receptor Tyrosine Kinase
16%
Gynecologic Cancer Survivors
16%
Recurrent Endometrial Cancer
16%
Confidence Interval
16%
Metastasis
15%
Uterine Serous Carcinoma
15%
Progression-free Survival
14%
Ovarian Cancer Cells
13%
AXL Inhibition
13%
Fallopian Tube
13%
Weight Loss
12%
Cervical Cancer
11%
Taxanes
11%
National Cancer Institute
11%
Randomized Controlled Trial
11%
Poor Prognosis
11%
Capivasertib
10%
E17K
10%
Behavioral Weight Loss
10%
Text Messaging
10%
AKT1
10%
Message-based
10%
Gynecologic Malignancies
10%
Non-randomized Trial
10%
Salophenes
10%
Iron(III)
10%
NRG Oncology
10%
Phase I Trial
10%
COVID-19 Pandemic Impact
10%
OR-PAM
10%
Extracellular Matrix Protein 1 (ECM1)
10%
High-grade Serous Ovarian Cancer (HGSOC)
10%
Tumor Burden
10%
Ovarian Cancer Patients
10%
Gynecological Cancer
9%
Malignancy
8%
Body Mass Index
8%
